275 related articles for article (PubMed ID: 24791854)
61. [Clinical features of essential thrombocythemia and primary myelofibrosis, depending on the molecular characteristics of disease].
Melikyan AL; Subortseva IN; Sudarikov AB; Kovrigina AM; Gilyazitdinova EA; Kolosheinova TI; Abdullaev AO; Treglazova SA
Ter Arkh; 2017; 89(7):4-9. PubMed ID: 28766534
[TBL] [Abstract][Full Text] [Related]
62. No increase of JAK2 46/1 haplotype frequency in essential thrombocythemia with CALR mutations: Functional effect of the haplotype limited to allele with JAK2V617F mutation but not CALR mutation.
Gau JP; Chen CC; Chou YS; Liu CJ; Yu YB; Hsiao LT; Liu JH; Hsu HC; Chiou TJ; Chen PM; Tzeng CH
Blood Cells Mol Dis; 2015 Jun; 55(1):36-9. PubMed ID: 25976465
[TBL] [Abstract][Full Text] [Related]
63. A meta-analysis comparing clinical characteristics and outcomes in CALR-mutated and JAK2V617F essential thrombocythaemia.
Yang Y; Wang X; Wang C; Qin Y
Int J Hematol; 2015 Feb; 101(2):165-72. PubMed ID: 25540065
[TBL] [Abstract][Full Text] [Related]
64. High resolution melting analysis: a rapid and accurate method to detect CALR mutations.
Bilbao-Sieyro C; Santana G; Moreno M; Torres L; Santana-Lopez G; Rodriguez-Medina C; Perera M; Bellosillo B; de la Iglesia S; Molero T; Gomez-Casares MT
PLoS One; 2014; 9(7):e103511. PubMed ID: 25068507
[TBL] [Abstract][Full Text] [Related]
65. Systematization of analytical studies of polycythemia vera, essential thrombocythemia and primary myelofibrosis, and a meta-analysis of the frequency of JAK2, CALR and MPL mutations: 2000-2018.
Mejía-Ochoa M; Acevedo Toro PA; Cardona-Arias JA
BMC Cancer; 2019 Jun; 19(1):590. PubMed ID: 31208359
[TBL] [Abstract][Full Text] [Related]
66. Identification of putative noncanonical driver mutations in patients with essential thrombocythemia.
Arai A; Yoshimitsu M; Otsuka M; Ito Y; Miyazono T; Nakano N; Obama K; Nakashima H; Hanada S; Owatari S; Nakamura D; Tokunaga M; Kamada Y; Utsunomiya A; Haraguchi K; Hayashida M; Fujino S; Odawara J; Tabuchi T; Suzuki S; Hamada H; Kawamoto Y; Uchida Y; Hachiman M; Ishitsuka K
Eur J Haematol; 2023 Jun; 110(6):639-647. PubMed ID: 36811253
[TBL] [Abstract][Full Text] [Related]
67. [Clinical significance of JAK2、CALR and MPL gene mutations in 1 648 Philadelphia chromosome negative myeloproliferative neoplasms patients from a single center].
Li MY; Chao HY; Sun AN; Qiu HY; Jin ZM; Tang XW; Han Y; Fu CC; Chen SN; Wu DP
Zhonghua Xue Ye Xue Za Zhi; 2017 Apr; 38(4):295-300. PubMed ID: 28468090
[No Abstract] [Full Text] [Related]
68. CALR mutation, MPL mutation and triple negativity identify patients with the lowest vascular risk in primary myelofibrosis.
Finazzi MC; Carobbio A; Cervantes F; Isola IM; Vannucchi AM; Guglielmelli P; Rambaldi A; Finazzi G; Barosi G; Barbui T
Leukemia; 2015 May; 29(5):1209-10. PubMed ID: 25482134
[No Abstract] [Full Text] [Related]
69. Differences in Hematological and Clinical Features Between Essential Thrombocythemia Cases With JAK2- or CALR-Mutations.
Kubuki Y; Shide K; Kameda T; Yamaji T; Sekine M; Kamiunten A; Akizuki K; Shimoda H; Tahira Y; Nakamura K; Abe H; Miike T; Iwakiri H; Tahara Y; Sueta M; Hashimoto K; Yamamoto S; Hasuike S; Hidaka T; Nagata K; Kitanaka A; Shimoda K
Ann Lab Med; 2017 Mar; 37(2):159-161. PubMed ID: 28029004
[No Abstract] [Full Text] [Related]
70. X chromosome inactivation analysis reveals a difference in the biology of ET patients with JAK2 and CALR mutations.
Allen C; Lambert JR; Linch DC; Gale RE
Blood; 2014 Sep; 124(13):2091-3. PubMed ID: 25139350
[TBL] [Abstract][Full Text] [Related]
71. An accurate, simple prognostic model consisting of age, JAK2, CALR, and MPL mutation status for patients with primary myelofibrosis.
Rozovski U; Verstovsek S; Manshouri T; Dembitz V; Bozinovic K; Newberry K; Zhang Y; Bove JE; Pierce S; Kantarjian H; Estrov Z
Haematologica; 2017 Jan; 102(1):79-84. PubMed ID: 27686378
[TBL] [Abstract][Full Text] [Related]
72. One thousand patients with essential thrombocythemia: the Florence-CRIMM experience.
Loscocco GG; Gesullo F; Capecchi G; Atanasio A; Maccari C; Mannelli F; Vannucchi AM; Guglielmelli P
Blood Cancer J; 2024 Jan; 14(1):10. PubMed ID: 38238287
[TBL] [Abstract][Full Text] [Related]
73. Driver mutations and prognosis in primary myelofibrosis: Mayo-Careggi MPN alliance study of 1,095 patients.
Tefferi A; Nicolosi M; Mudireddy M; Szuber N; Finke CM; Lasho TL; Hanson CA; Ketterling RP; Pardanani A; Gangat N; Mannarelli C; Fanelli T; Guglielmelli P; Vannucchi AM
Am J Hematol; 2018 Mar; 93(3):348-355. PubMed ID: 29164670
[TBL] [Abstract][Full Text] [Related]
74. A rare CALR variant mutation and a review of CALR in essential thrombocythemia.
Diep R; Metjian A
J Thromb Thrombolysis; 2018 Apr; 45(3):457-462. PubMed ID: 29411299
[TBL] [Abstract][Full Text] [Related]
75. It is time to change thrombosis risk assessment for PV and ET?
Passamonti F; Caramazza D; Mora B; Casalone R; Maffioli M
Best Pract Res Clin Haematol; 2014 Jun; 27(2):121-7. PubMed ID: 25189723
[TBL] [Abstract][Full Text] [Related]
76. CALR mutational status identifies different disease subtypes of essential thrombocythemia showing distinct expression profiles.
Zini R; Guglielmelli P; Pietra D; Rumi E; Rossi C; Rontauroli S; Genovese E; Fanelli T; Calabresi L; Bianchi E; Salati S; Cazzola M; Tagliafico E; Vannucchi AM; Manfredini R;
Blood Cancer J; 2017 Dec; 7(12):638. PubMed ID: 29217833
[TBL] [Abstract][Full Text] [Related]
77. [Analysis of CALR, JAK2 and MPL gene mutations in BCR-ABL negative myeloproliferative neoplasms].
Ouyang Y; Qiao C; Wang J; Xiao L; Zhang S
Zhonghua Yi Xue Za Zhi; 2015 May; 95(18):1369-73. PubMed ID: 26178351
[TBL] [Abstract][Full Text] [Related]
78. CALR and ASXL1 mutation analysis in 190 patients with essential thrombocythemia.
Shen H; Chao H; Ding Z; Feng Y; Cen J; Pan J; He J; Zhou M; Chen Z; Chen S
Leuk Lymphoma; 2015 Mar; 56(3):820-2. PubMed ID: 25005031
[No Abstract] [Full Text] [Related]
79. [Clinical Analysis of 66 Patients with Essential Thrombocytopenia].
Zhang LJ; Shi YY; Chen Y; Gan YM; Shi WT; Chen KK; Ding BH; He ZM; Wang CL; Yu L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Aug; 28(4):1321-1325. PubMed ID: 32798420
[TBL] [Abstract][Full Text] [Related]
80. Mutation status of essential thrombocythemia and primary myelofibrosis defines clinical outcome.
Asp J; Andréasson B; Hansson U; Wasslavik C; Abelsson J; Johansson P; Palmqvist L
Haematologica; 2016 Apr; 101(4):e129-32. PubMed ID: 26768689
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]